Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 62

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 62
---
 MIRA’s stockholders approve the proposals to be presented to MIRA’s stockholders for consideration at the MIRA Annual Meeting as contemplated by this proxy statement.

Ownership Interests

As of June 12, 2025, MIRA’s directors and executive officers (including affiliates) beneficially owned, in the aggregate approximately 23.6% of the outstanding shares of MIRA. Approval of Proposals Nos. 1 and 2 requires the affirmative vote of a majority of the votes cast virtually or by proxy at the MIRA Annual Meeting.

Beneficial Ownership of SKNY

Several beneficial owners of SKNY are also related parties of MIRA. For example, MIRA’s CEO, Erez Aminov, and owner of 19.23% of MIRA also holds a beneficial ownership interest of 3,000,000 shares, or 13.6% of SKNY, and MIRA’s director Dr. Denil Shekhat holds a beneficial ownership interest of under 1.0% of SKNY as well as serving as the trustee of the 2023 YEA Irrevocable Trust, which holds 2,739,000 shares of SKNY. Furthermore, shares of MIRA held by several trusts or individuals, also own shares of SKNY. Specifically, (i) Bay Shore Trust holds 2,540,270 shares of MIRA, 1,000,000 shares of MIRA issuable pursuant to warrants held by the Bay Shore Trust that are immediately exercisable and 7,128,532 shares, or 32.3% of SKNY, and (ii) the Celeste J Williams Lifetime QTIP Trust holds of 779,047 shares of MIRA and 576,150, or 2.6% shares of SKNY.

MIRALOGX LLC

Each of MIRA and SKNY license their respective intellectual property from MIRALOGX LLC. Such license agreements call for cash royalty payments to MIRALOGIX that begin upon the first revenue realized from the licensed products and that continue thereafter regardless of whether further revenues are received from such licensed products.

Merger-Related Compensation of Executive Officers

In connection with the approval of the Merger, the Board previously adopted an Executive Compensation Plan that provides for certain performance-based compensation arrangements for executive officers, including the Chief Executive Officer. These arrangements are tied to the successful completion and overall value of the Merger.

Telomir Pharmaceuticals, Inc. Shares Held by MIRA Pharmaceuticals, Inc.